The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-15 and is reviewed periodically as new material appears.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
After the Avar Khaganate collapsed in the 790s, the First Bulgarian Empire became the dominant power of the region, occupying lands as far as the river Tisa. The First Bulgarian Empire had a mixed population consisting of the Bulgar conquerors, Slavs and Vlachs (or Romanians) but the Slavicisation of the Bulgar elite had already begun in the 9th century. Following the conquest of southern Transylvania around 830, people from the Bulgar Empire mined salt at the local salt mines. The Council of Preslav declared Old Church Slavonic the language of liturgy in the country in 893. The Vlachs also adopted Old Church Slavonic as their liturgical language. The Magyars (or Hungarians) took control of the steppes north of the Lower Danube in the 830s, but the Bulgarians and the Pechenegs forced them to abandon this region for the lowlands along the Middle Danube around 894. Centuries later, the Gesta Hungarorum wrote of the invading Magyars' wars against three dukes—Glad, Menumorut and the Vlach Gelou—for Banat, Crișana and Transylvania. The Gesta also listed many peoples—Slavs, Bulgarians, Vlachs, Khazars, and Székelys—inhabiting the same regions. The reliability of the Gesta is debated. Some scholars regard it as a basically accurate account, others describe it as a literary work filled with invented details. The Pechenegs seized the lowlands abandoned by the Hungarians to the east of the Carpathians. Byzantine missionaries proselytised in the lands east of the Tisa from the 940s and Byzantine troops occupied Dobruja in the 970s.
== Bibliography == "Hudson River Chain", Harper's Encyclopedia of United States History, Vol. IV, p. 447, Harper & Brothers Publishers, 1905. Information plaques at Trophy Point at West Point, New York. "West Point Fortifications", Scribd U.S. Military Academy Department of History, West Point Fortifications Staff Ride Notecards, second edition (1998)
== Staining principle == There is much more phosphotungstic acid in the solution than hematein. The phosphotungstic acid binds all of the available hematein to form a blue lake pigment. This lake stains the muscle cross striations, fibrin, nuclei, and other tissue elements blue. The rest of the phosphotungstic acid stains the red-brown components, such as collagen.
== The Future Possibilities of Venomics == The field of venomics has been vastly revamped since its origin in the 20th century and continues to be improved with contemporary methods such as next generation sequencing and nuclear magnetic resonance spectroscopy. From this trend, it would seem that venomics will be progressively enhanced in its capabilities through the persistent technological advancements of the 21st century. As previously mentioned, a potential route that can be expanded upon further by venomics could be venom-specific molecules being co-opted into specialised medicines. The first example of this was in the early 1970s, when Captopril was found to be an inhibitor of angiotensin converting enzymes (ACE) and had the means of treating hypertension in people. Glenn King discusses the current state of venom-derived drugs, with six drugs derived from venom being FDA-approved and ten more currently being under clinical trials. Michael Pennington gives a detailed update on the current landscape of venom-derived drugs and the potential future of the field (Table 1). Anti-venoms is another branch of medicine, which needs to be improved due to the problems many developing countries face with venomous animals. Places like south/southeast Asia and sub-Saharan Africa are where many cases of both morbidity (limb amputation) and mortality take place.
Sources: en.wikipedia.org
== Transport == Billericay is a part of the London commuter belt, with a high proportion of people working in the City and other central parts of London. The town is served by Billericay railway station, which lies on the Shenfield to Southend Line. Services between London Liverpool Street, Shenfield and Southend Victoria are operated by Greater Anglia; some trains in peak hours run to Southminster. Local bus services are operated by First Essex, which connect the town with Chelmsford, Basildon, Brentwood and Wickford. Many routes connect to the station's bus stop, including service 300 which operates regularly between Basildon and Chelmsford. School services are provided by First Essex and NIBS Buses. The town was established at the Sun Corner crossroads of two roads:
=== Immune function === Vitamin A plays an important role in the body's immune function, both the adaptive response, and to help the body fight off infection. The anti-inflammatory effects of vitamin A also contribute to repairing mucosal cells that can be damaged by an infection. For these reasons, there have been quite a few studies looking at the potential role that Vitamin A supplementation may play in improving an immune response or to helping the body fight off an infection. The evidence supporting vitamin A supplementation for children under the age of 7 years to prevent upper respiratory tract infections is weak, and the weak evidence from low-quality clinical trials does not support vitamin A as being effective or having a benefit. More research is needed to consider different doses, the ages and populations of people who may potentially benefit, and the length of treatment.
== Signaling pathway == The essential function of the TCR complex is to identify specific bound antigen derived from a potentially harmful pathogen and elicit a distinct and critical response. At the same time it has to ignore any self-antigen and tolerate harmless antigens such as food antigens. The signal transduction mechanism by which a T cell elicits this response upon contact with its unique antigen is termed T-cell activation. Upon binding to pMHC, the TCR initiates a signaling cascade, involving transcription factor activation and cytoskeletal remodeling resulting in T-cell activation. Active T cells secrete cytokines, undergo rapid proliferation, have cytotoxic activity and differentiate into effector and memory cells. When the TCR is triggered, T cells form an immunological synapse allowing them to stay in contact with the antigen presenting cell for several hours. On a population level, T-cell activation depends on the strength of TCR stimulation, the dose–response curve of ligand to cytokine production is sigmoidal. However, T-cell activation on a single cell level can be characterized by a digital switch-like response, meaning the T cell is fully activated if the stimulus is higher than a given threshold; otherwise the T cell stays in its non-activated state. There is no intermediate activation state. The robust sigmoid dose-response curve on population level results from individual T cells having slightly different thresholds. T cells need three signals to become fully activated.
== Arthropathies and related disorders (710–719) == 710 Diffuse diseases of connective tissue 710.0 Systemic lupus erythematosus 710.2 Sjögren's syndrome 710.3 Dermatomyositis 710.4 Polymyositis 710.5 Eosinophilia myalgia syndrome 710.9 Connective tissue disease, unspec. 711 Arthropathy associated with infections 712 Crystal arthropathies 712.1 Chondrocalcinosis due to dicalcium phosphate crystals 712.2 Chondrocalcinosis due to pyrophosphate crystals 712.3 Chondrocalcinosis, cause unspecified pseudogout 712.8 Other specified crystal arthropathies 712.9 Unspecified crystal arthropathy 713 Arthropathy, endocrine disorders 713.1 Arthropathy, gastrointestinal conditions 714 Rheumatoid arthritis and other inflammatory polyarthropathies 714.0 Rheumatoid arthritis 714.3 Polyarticular juvenile rheumatoid arthritis 715 Osteoarthrosis and allied disorders 715.09 Osteoarthrosis, generalized, multiple sites 715.11 Osteoarthrosis, shoulder 715.14 Osteoarthrosis, hand 715.15 Osteoarthrosis, hip 715.16 Osteoarthrosis, knee 715.17 Osteoarthrosis, ankle/foot 715.9 Osteoarthrosis, unspec. 716 Other and unspecified arthropathies 716.1 Arthropathy, traumatic, unspec. 716.9 Arthropathy, unspec. 717 Internal derangement of knee 717.1 Derangement of anterior horn of medial meniscus 717.42 Derangement of lateral meniscus 717.7 Chondromalacia of patella 717.9 Derangement, internal, knee, unspec.
CK-MB (creatine phosphokinase-MB), also known as CPK-MB, is a cardiac marker used to assist diagnoses of an acute myocardial infarction, myocardial ischemia, or myocarditis. It measures the blood level of CK-MB (a creatine kinase hybrid of muscle and brain subunits), the bound combination of two variants (isoenzymes CKM and CKB) of the enzyme phosphocreatine kinase. In some locations, the test has been superseded by the troponin test. However, recently, there have been improvements to the test that involve measuring the ratio of the CK-MB1 and CK-MB2 isoforms. The newer test detects different isoforms of the B subunit specific to the myocardium whereas the older test detected the presence of cardiac-related isoenzyme dimers. Many cases of CK-MB levels exceeding the blood level of total CK have been reported, especially in newborns with cardiac malformations, especially ventricular septal defects. This reversal of ratios is in favor of pulmonary emboli or vasculitis. An autoimmune reaction creating a complex molecule of CK and IgG should be taken into consideration.
Sources: en.wikipedia.org
== Early life and education == Sur did his early schooling at the St. Joseph's Collegiate School, Allahabad. He received a Bachelor of Technology degree in electrical engineering from the Indian Institute of Technology in Kanpur (IIT Kanpur) in 1974, and Master of Science and PhD degrees in electrical engineering in 1975 and 1978, respectively, from Vanderbilt University in Nashville. After postdoctoral research at Stony Brook University, he was appointed to the faculty of Yale University School of Medicine in 1983.
Wind direction plays a critical role in shaping the inland extent of X. parietina. Southwesterly winds in the warmer months carry marine aerosols further inland, while easterly storms contribute additional sea salt deposition through precipitation. The influence of these aerosols is evident in Maine cemeteries: X. parietina is more frequent in open cemeteries exposed to prevailing winds, compared to wooded cemeteries, which block or capture airborne sea salts, and have significantly lower frequencies of the lichen. In recent decades, inland populations of X. parietina have been discovered in southern Ontario, suggesting an expansion beyond its traditionally coastal range. Once considered extirpated from the region, the species was rediscovered growing on trees in several inland locations. This inland occurrence raises questions about whether the lichen has reestablished after a long absence or has persisted undetected for decades. The expansion may be linked to increasing nitrogen deposition from agricultural runoff and air pollution, which create conditions favorable for nitrophilous lichens like X. parietina. Another possible factor in its inland spread is the widespread use of road salt in Ontario over the past 50–70 years. Since X. parietina thrives in salt-rich coastal environments, roadside salt deposition may have provided an artificial habitat, mimicking the chemical conditions of maritime regions.
Moreover, engineered knottins have shown significant promise as therapeutics, imaging agents, and targeting agents for chemotherapy. The mammalian proteins Agouti signalling peptide and Agouti related peptide are the only known mammalian examples of this motif. Both are neuropeptides involved in cell signalling. The former is responsible for hair (fur) colouration. The motif is similar to the cyclic cystine knot or cyclotide, but lacks the cyclisation of the polypeptide backbone which is present in the latter family. The growth factor cystine knot (GFCK) is similar to the ICK but its topology is such that it is the bond between the first and fourth disulfide which threads through the loop.
== Overview == The series focuses on Olivia Pope and her crisis management firm, Olivia Pope & Associates, and its staff, as well as staff at the White House in Washington D.C. as political scandals occur and they must try to deal with them.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.